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Introduction
It is now known that adipose tissue is a dynamic 
endocrine organ in its own right, secreting a number of 
biologically active proteins, also known as adipokines [1]. 
One of these adipokines, adiponectin, has been recog-
nised to play a major role in the pathogenesis of the 
metabolic syndrome. In recent years, its role in the 
modulation of inﬂ   ammation has become increasingly 
apparent. Th  ere has therefore been a spate of research 
examining its role in critical illness and sepsis. In this 
review we will discuss the biology of adiponectin and its 
physiological role, with a predominant emphasis on its 
role in inﬂ  ammation and critical illness.
The secretory function of adipose tissue
Th   e source of adipokines is either the adipocytes them-
selves or the stromal vascular fraction within adipose 
tissue, comprising preadipocytes, endothelial cells, ﬁ  bro-
blasts, leukocytes and macrophages [1]. Resident stromal 
macrophages are a source of IL-10 and arginase. 
However, ‘classically activated’ macrophages recruited 
from the circulation to obese adipose tissue secrete the 
pro-inﬂ   ammatory cytokines TNF-α, inducible nitric 
oxide synthase, and IL-6. Adipocytes are responsible for 
the production of adiponectin, leptin, angiotensinogen 
and retinol-binding protein. Some adipokines, including 
monocyte chemoattractant protein-1 and apelin, are 
produced by both fractions [1,2].
Adiponectin
Adiponectin is a protein produced and secreted almost 
exclusively by adipocytes [3]. First described over a 
decade ago, the interest in the biology of adiponectin was 
spurred by the discovery of measurable concentrations in 
plasma, its structural resemblance to complement factor 
C1q and the consistent ﬁ   nding of decreased levels in 
obesity [4]. Adiponectin circulates in high concentrations 
in healthy adults and mice, accounting for 0.01% of total 
plasma protein and its plasma levels are a thousand times 
that of leptin [5]. Circulating levels of adiponectin range 
between 2 and 30 μg/ml in humans [4,6] and are generally 
higher in females than males [7]. Th   is sexual dimorphism 
has been attributed to the eﬀ   ect of testosterone on 
adiponectin secretion [8].
Th  e gene encoding human adiponectin has been 
mapped to chromosome 3q27 [9]. In serum, adiponectin 
exists as three main forms: trimers, hexamers and high-
molecular weight (HMW) multimers. To create these 
forms, a number of post-translational modiﬁ  cations are 
required (Figure 1).
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involved in the secretion of adiponectin from adipocytes 
are well-described in several excellent reviews [10,11]. 
Murine studies show the half-life of circulating 
adiponectin to be 75 minutes with clearance mediated by 
the liver. HMW adiponectin has the slowest plasma 
clearance rate and serum levels remain fairly constant, 
despite rapid turnover [12]. Th   ere is evidence of elevated 
levels of adiponectin in chronic kidney disease and 
reduced clearance rates have been observed in animal 
models of end-stage renal disease [13]. A reduction in 
serum adiponectin has been observed after renal 
transplantation in humans, suggesting a possible role for 
the kidney in adiponectin clearance [14].
Th  ree adiponectin receptors, AdipoR1, AdipoR2 and 
T-cadherin, have been identiﬁ  ed. AdipoR1 is ubiquitous, 
but is most abundantly expressed in skeletal muscle and 
is linked to activation of AMP-activated kinase (AMPK) 
pathways. AdipoR2 is most abundantly expressed in the 
liver and is associated with activation of peroxisome 
proliferator-activated receptor (PPAR)-α pathways 
[15,16]. A third receptor for adiponectin, T-cadherin, 
expressed on vascular endothelial cells and smooth 
muscle, is a receptor for hexameric and HMW adipo-
nectin [17]. Th   e activation of AdipoR1 and R2 results in 
increased hepatic and skeletal muscle fatty acid oxidation, 
increased skeletal muscle lactate production, reduced 
hepatic gluconeogenesis, increased cellular glucose up-
take and inhibition of inﬂ  ammation and oxidative stress 
[18,19]. Activation of T-cadherin is protective in vascular 
endothelial cells against oxidative stress-induced apop-
tosis [20] and is strongly expressed in regions of 
atherosclerosis [21].
Adiponectin in health and disease
Th  e precise physiological role of adiponectin is unclear. 
Adiponectin does not seem to be essential for survival as 
knockout (KO) mice survive with minimal lethality [22]. In 
humans, adiponectin is an insulin-sensitizing, vascular-
protective, anti-inﬂ  ammatory protein [4,23,24] asso  cia  ted 
with a more favourable lipoprotein subclass proﬁ  le [2].
To date, most of our understanding of adiponectin has 
been in its association with metabolic and cardiovascular 
health. Hypoadiponectinaemia is associated with obesity, 
insulin resistance and type 2 diabetes [4,23,24], as well as 
atherosclerosis, hypertension and coronary artery disease 
[25]. Low circulating levels, particularly of the HMW 
component [26], are also a strong risk marker for the 
development of the metabolic syndrome and type 2 
diabetes [27,28] (Table 1).
Recently, several observations point to a potential role 
for adiponectin in a variety of inﬂ  ammatory  diseases. 
Elevated serum adiponectin levels have been found in 
association with systemic lupus erythematosus [29], 
cystic ﬁ  brosis [30], inﬂ  ammatory bowel disease [31] and 
rheumatoid arthritis [32]. Th  e  signiﬁ  cance of these ﬁ  nd-
ings is not yet understood. Whether the high adipo  nectin 
may be part of the protective response to the underlying 
inﬂ  ammation, or those with low adiponectin (or those 
less able to increase adiponectin) may be more prone to 
inﬂ   ammation, or the changes purely represent an 
epiphenomenon need further elucidation. In this context, 
its role in the inﬂ  ammatory response of critical illness is 
further discussed below.
Adiponectin in critical illness
Adiponectin and acute infl  ammation
Adiponectin exerts an anti-inﬂ  ammatory eﬀ  ect through 
activation of all three receptors. Several mechanisms have 
been suggested, including direct actions on inﬂ  am  matory 
cells, actions on NF-κB, and interaction with TNF-α.
Figure 1. The structure and multimerization of adiponectin. 
(a) The domain structure of human adiponectin. (b) Adiponectin 
multimerization and analysis by velocity sedimentation. Separation 
of low-molecular weight (LMW) and high-molecular weight (HMW) 
multimers was performed by centrifugation on a 5 to 20% sucrose 
density gradient. Fractions 2 to 7 of the gradient contain the LMW 
multimers, while the HMW multimers are found in fractions 8 to 11. 
Reproduced from Whitehead JP and colleagues [5].
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Peripheral blood mononuclear cells (monocytes, natural 
killer (NK) cells and T and B lymphocytes) express adipo-
nectin receptors 1 and 2 [33].
Adiponectin inhibits the growth of myelomonocytic 
progenitors and the functioning of mature macrophages 
[34], suppresses macrophage-to-foam cell transformation 
[35], stimulates macrophage production of the anti-
inﬂ  am  matory cytokine IL-10 [36], inhibits both TNF-α-
induced monocyte adhesion and adhesion molecule 
(vascular cell adhesion molecule (VCAM)-1, E-selectin 
and intercellular adhesion molecule (ICAM)-1) surface 
expression on endothelial cells [37] and inhibits Toll-like 
receptor-mediated NF-κB activation in macrophages 
[38]. Adiponectin also inhibits the production of reactive 
oxygen species in human neutrophils [39]. Th  ough of 
unclear signiﬁ   cance, leukocyte elastase produced by 
neutro  phils and activated monocytes is able to cleave 
adiponectin, producing a fragment containing the 
globular domain of the adiponectin molecule [40].
Most of these data have been generated from bench 
studies and clear dose-response relationships have not 
been demonstrated. For example, Yokota and colleagues 
[34] used in vitro concentrations of 0 to 50 mcg/ml of 
adiponectin, which approximate circulating physiological 
concentrations. However, Magalang and colleagues [39] 
were able to demonstrate suppression of free radical 
formation at doses of 0.001 to 1 mcg/ml, which are clearly 
well below the normal concentrations.
Actions on NF-κB
NF-κB, a key player in the inﬂ   ammatory response, is 
involved in the regulation of cellular functions, including 
the stress response. Th   e action of adiponectin on NF-κB 
pathways is complex, being both stimulatory and 
inhibitory.
Initially, higher order multimers of adiponectin were 
reported to activate NF-κB pathways in myocytes [41]. 
Activation of NF-κB pathways by adiponectin has also 
been observed in vascular endothelial cells [42] and 
ﬁ  broblasts [43], as well as hepatocytes [44], where NF-κB 
activation induces secretion of a protective chemokine. 
Counteracting the above evidence is the demonstration 
of an inhibitory eﬀ  ect of adiponectin on the NF-κB path-
ways. Adiponectin suppresses lipopolysaccharidase (LPS)-
induced NF-κB activation in adipocytes [45], suppresses 
TNF-α-induced NF-κB pathways in endo  the  lial cells [46] 
and inhibits NF-κB pathways in macrophages [47].
Adiponectin is also able to regulate the cytotoxicity of 
NK cells. Adiponectin activates AMP-activated kinase 
pathways in NK cells, which, in turn, inhibit IL-2-induced 
NF-κB activation. Th  is results in the suppression of the 
IL-2-enhanced cytotoxic activity of NK cells without 
aﬀ  ecting basal NK cell cytotoxicity [48].
Th  e importance of the dual nature of adiponectin 
eﬀ  ects on NF-κB is not clearly understood and raises 
questions about the timing and the signiﬁ  cance of each of 
these eﬀ  ects. When it is stimulatory, what initiates the 
change to an inhibitory eﬀ  ect, and which signalling mole-
cules trigger the change are not precisely understood 
[49].
Interaction with TNF-α
Adiponectin may play a role in the downregulation of 
inﬂ   ammatory responses involving TNF-α. An inverse 
relationship has been shown to exist between TNF-α and 
adiponectin [50,51]. Th  is eﬀ  ect is bi-directional, that is, 
primary changes in TNF-α can inﬂ  uence  adiponectin 
concen  trations and vice versa. TNF-α suppresses the 
expression and secretion of adiponectin from murine and 
human adipocytes in cell cultures [52,53]. Conversely, 
primary alterations in adiponectin result in inverse 
correlation with TNF. Adiponectin KO mice show high 
levels of TNF-α mRNA in adipose tissue and high plasma 
TNF-α concentrations, with reversal of these changes 
seen following viral-mediated adiponectin expres  sion in 
these mice [24]. Additionally, adiponectin strongly 
inhibits LPS-induced TNF-α gene expression in macro-
phages [34]
Th  e inverse correlation demonstrated between adipo-
nectin and TNF-α in cell cultures has not been 
consistently reproduced in human subjects. Keller and 
colleagues [54] induced endotoxaemia in 23 healthy 
humans. Following endotoxin injection, TNF-α and IL-6 
levels increased; however, there was no signiﬁ  cant change 
in the level of adiponectin. Anderson and colleagues [55] 
explored the relationship between acute inﬂ  ammation 
and adipokines within a cohort of 20 healthy humans. 
Table 1. Physiological functions of adiponectin 
Enhanced insulin sensitivity
  Increased muscle glucose uptake
  Decreased hepatic gluconeogenesis
Increased lipid metabolism
  Fatty acid oxidation in skeletal muscle and liver
  VLDL catabolism in skeletal muscle with reduction in plasma triglycerides
Vascular protection
  Preservation of endothelial cell function
 Anti-atherogenic
Hepato-protective
? Protective against malignancy
Anti-infl  ammatory
  Decreases TNF-α, IL-6, CRP
  Regulation of infl  ammatory cell function
  ? Neutralises endotoxin
CRP, C-reactive protein; VLDL, very-low-density lipoprotein.
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blood leukocyte, monocyte and adipose tissue TNF-α 
and IL-6 but with no signiﬁ  cant changes in total plasma 
adiponectin or complex distribution. AdipoR1 and R2 
receptor downregulation, however, was evident. Although 
adiponectin levels did not change, the downregulation of 
adiponectin receptors following endotoxaemia suggested 
attenuation of adiponectin’s insulin sensitising and 
inﬂ  ammatory signalling functions [55].
In animal models of sepsis, adiponectin deﬁ  ciency is 
associated with a marked increase in inﬂ  ammatory 
mediator status and exacerbation of hepatic injury 
[56,57]. In a recent study of 33 patients with severe sepsis 
or septic shock, a similar inverse correlation was demon-
strated [58]. Th   is consistent ﬁ  nding raises the possibility 
that modulation of adiponectin in sepsis may be a 
potential therapeutic target to attenuate the inﬂ  am-
matory response.
Th  e anti-inﬂ   ammatory properties of adiponectin are 
summarised in Figure 2.
Adiponectin and sepsis
Th   e early observations that adiponectin antagonises the 
inﬂ  ammatory eﬀ  ects of TNF-α, negatively correlates with 
plasma TNF-α levels and shows structural homology to 
complement factor C1q led researchers to further investi-
gate the relationship between adiponectin and sepsis. 
Both animal and human data have been reported.
Animal data
In rats with induced polymicrobial sepsis, plasma adipo-
nectin levels negatively correlated with plasma endotoxin 
and TNF-α levels [59]. Adiponectin was found to directly 
bind LPS and suppress limulus amoebocyte lysate in 
vitro. Th   is animal model also provided the ﬁ  rst evidence 
that the two adipokines, adiponectin and TNF-α, 
inversely regulate each other’s circulating concentration.
Uji and colleagues [56] reported that adiponectin KO 
mice were more susceptible to polymicrobial sepsis than 
wild-type mice. Th  ey investigated the role of adiponectin 
in sepsis using a murine model of caecal ligation and 
perforation (CLP). Adiponectin KO and wild-type mice 
were subjected to CLP and the eﬀ  ects of rosiglitazone (a 
PPAR-γ agonist) on survival were investigated. Although 
the authors concluded that adiponectin deﬁ  ciency  was 
associated with excess mortality and high cytokine levels, 
several questions were raised by the study. Plasma 
endotoxin and IL-6 levels in adiponectin KO mice after 
CLP were signiﬁ  cantly higher than in wild-type mice only 
at 24 hours, not earlier. Moreover, other pharmaco  dynamic 
Figure 2. The anti-infl  ammatory actions of adiponectin. NK, natural killer.
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diﬀ   erences in glucose concentrations or high-density 
lipoprotein cholesterol levels between the two groups. 
Rosiglitazone improved mortality only in the wild-type 
mice, not KO mice, and cytokine levels were not presented 
in this subgroup. It is likely, therefore, that the beneﬁ  cial 
eﬀ  ects of adiponectin on mortality may operate through 
pathways other than its anti-inﬂ  am  matory eﬀ  ects.
Not all studies support an anti-inﬂ  ammatory role for 
adiponectin. A signiﬁ   cant reduction in survival of 
adiponectin-gene deﬁ   cient mice was found following 
CLP, as well as a greater inﬂ  ux of peritoneal neutrophils 
in these mice following thioglycollate-induced peritonitis 
[60]. However, the administration of recombinant trimeric 
adiponectin did not signiﬁ  cantly attenuate VCAM and 
ICAM expression in thioglycollate-challenged adipo-
nectin KO mice, thus raising questions about its anti-
inﬂ  ammatory beneﬁ  cial role [60]. Th   e improved survival 
in wild-type mice in this study compared to the KO mice 
raises the possibility that adiponectin may provide a 
survival beneﬁ   t through alternative, as yet unknown 
mechanisms.
Another study arguing against an anti-inﬂ  ammatory 
role for adiponectin in sepsis is that of Pini and colleagues 
[61]. Th   ey failed to ﬁ  nd a diﬀ  erence in the inﬂ  ammatory 
response generated by high-dose LPS or concanavalin A 
administration in adiponectin KO mice compared with 
wild type. Th   is lack of positive ﬁ  ndings was suggested to 
be due to the particular strain of adiponectin KO mice 
used in the study.
A murine study investigating the role of adipokines in 
mice exposed to zymosan, a cell wall product of yeast, 
showed a signiﬁ   cant decrease in serum adiponectin 
during zymosan-induced peritonitis in wild-type mice. 
Th   e role of adiponectin in the inﬂ  ammatory process did 
not appear signiﬁ   cant, however, with adiponectin KO 
mice actually demonstrating a minor reduction in their 
peritoneal inﬂ  ammatory cell inﬁ  ltrate, and no signiﬁ  cant 
changes in circulating cytokine levels when compared to 
wild-type mice [62].
Th   e data from animal trials are summarised in Table 2.
Human studies
Limited human studies of adiponectin in critical illness 
exist. Lower levels of adiponectin have been found in 
critically ill patients [58,63-65]. Additionally, Venkatesh 
and colleagues [64] described a strong association 
between plasma cortisol and adiponectin, an inverse 
correlation between plasma C-reactive protein and 
adiponectin, as well as a linear response between sickness 
severity and plasma adiponectin. Levels of C-reactive 
protein in plasma and adipose tissue negatively correlate 
with adiponectin [64,66,67].
A recent study of patients with acute respiratory failure 
showed that increased plasma adiponectin levels 
measured within 48 hours of respiratory failure are 
associated with mortality [68].
In a study of paediatric patients with sepsis, increased 
levels of HMW adiponectin were found in the septic shock 
cohort on day 1 and the plasma levels correlated with risk of 
mortality scores. Th  is was associated with an increase in 
PPAR-γ activity in peripheral blood mono  nuclear cells [69].
Th   e human data are summarised in Table 3.
Modulation of adiponectin in critical illness
Given the abundance of data supporting the beneﬁ  cial 
role of adiponectin as a modulator of inﬂ  ammation, the 
question arises whether this will play a role in critical 
illness. Several lines of evidence point to this. Firstly, 
serum adiponectin concentrations are inversely 
Table 2. Data compiled from animal studies in infl  ammation and sepsis 
Year Reference  Data
2002 Maeda  et al. [24]  Delayed clearance of free fatty acids and increased plasma TNF-α in adiponectin KO mice
2006 Tsuchihashi  et al. [59]  Rat CLP model shows that adiponectin negatively correlates with plasma endotoxin and TNF-α
2006 Pini  et al. [61]  No signifi  cant diff  erence in the infl  ammatory response generated by LPS and concanavalin A administration to 
    wild-type and adiponectin KO mice
2008 Teoh  et al. [60]  Mouse CLP and thioglycollate-induced peritonitis produces a reduction in survival of adiponectin KO mice 
2008 Pini  et al. [62]  Reduction in circulating adiponectin levels during acute infl  ammation secondary to zymosan-induced peritonitis in 
    wild-type mice. Adiponectin does not appear to infl  uence the infl  ammatory response
2009 Uji et al. [56]  Mouse CLP model showed adiponectin KO mice are more susceptible to polymicrobial sepsis; higher circulating 
    endotoxin in adiponectin KO mice; PPAR-γ administration prior to CLP improved mortality in wild type, but not 
    adiponectin KO mice
2009 Leuwer  et al. [80]  Following injection of LPS in mice, adiponectin mRNA levels fell in white adipose tissue (epididymal, perirenal and 
    subcutaneous), MCP-1 and IL-6 mRNA rose in all three depots and TNF-α mRNA rose in epididymal and perirenal sites 
2010 Uji  et al. [57]  Adiponectin KO and wild-type mice were subjected to CLP. KO mice showed higher circulating levels of pro-
    infl  ammatory cytokines and greater evidence of hepatic injury than wild-type mice
CLP, caecal ligation and perforation; KO, knockout; LPS, lipopolysaccharidase; MCP-1, monocyte chemoattractant protein-1; PPAR, peroxisome proliferator-activated 
receptor.
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both cardiovascular disease and critical illness [59,70]. 
Secondly, a number of studies have reported low levels of 
adiponectin in critical illness [64]. Hypoadiponectinaemia 
is also associated with impaired endothelium-dependent 
vasorelaxation [71]. Data in patients with viral infections 
and human experimental endotoxaemia suggest altered 
release patterns of adiponectin in these states [54,72]. 
Th  e biochemical features of critical illness, that is, 
hyperglycaemia and cytokinaemia, are also biomarkers 
for hypoadiponectinaemia. Finally, the increasing numbers 
of patients with an elevated body mass index and obesity 
being admitted to intensive care units also raises the 
prospect of adiponectin playing a role in their underlying 
pathophysiology. Based on the above set of hypotheses, 
one could advance the argument that modulation of 
adiponectin in critical illness may lead to improved 
inﬂ  ammatory response, improved glucose tolerance and 
reduced vasopressor requirement.
It therefore leads to the next question of whether 
adiponectin levels can be modulated. Despite recombi-
nant adiponectin being widely used in the research 
setting, there are factors that make the production and 
therapeutic administration of adiponectin challenging. 
Full-length adiponectin is a complex molecule that 
undergoes signiﬁ   cant posttranslational modiﬁ  cations, 
circulates in very high concentrations and has a short 
plasma half-life [73].
An alternative option is the development of therapeutic 
agents that modulate and enhance expression and 
secre  tion of adiponectin from human cells [73]. 
Th   iazolidine  diones are high-aﬃ   nity ligands for PPAR- γ 
[74] and have strong insulin-sensitising eﬀ  ects [75]. Th  ey 
enhance the expression of adiponectin mRNA within 
adipocytes [52] and increase the plasma concentration of 
adiponectin, with a speciﬁ   c increase in the HMW 
component [76]. It has recently been shown that 
thiazolidinediones may result in increased secretion of 
HMW adiponectin from adipocytes, producing the 
elevated circulating levels [77]. Treatment with 
fenoﬁ   brate results in an increase in serum HMW 
adiponectin [78], as does niacin therapy [79], despite 
neither therapies showing an improvement in insulin 
sensitivity.
Another possibility to modulate levels would be to 
manipulate the clearance of adiponectin. Adiponectin is 
ultimately cleared by the liver, but little else is understood 
about clearance mechanisms [12]. Th   e method of clear-
ance may diﬀ  er between each molecular weight isoform. 
Large amounts of adiponectin are continually produced, 
but it has a relatively short half-life, suggesting that 
clearance pathways must play a very signiﬁ  cant role in 
controlling circulating levels.
Conclusion
Adiponectin is a newly described hormone that has a 
wide range of physiological and metabolic eﬀ  ects. It also 
appears to be cardioprotective and involved in modulat-
ing the inﬂ   ammatory response. Its role in systemic 
inﬂ  ammation and critical illness is not well-deﬁ  ned and 
Table 3. Data compiled from human studies in infl  ammation and sepsis 
Year Reference  Data
2000 Yokota  et al. [34]  In vitro studies of human myeloid cell lines show that adiponectin is a negative regulator of myelomonocytic 
    progenitor growth and downregulates the infl  ammatory response
2003 Keller  et al. [54]  Following induction of endotoxaemia in healthy humans, there was no signifi  cant alteration in adiponectin levels 
    (healthy subjects n = 23: 4 females, 19 males)
2006 Tsuchihashi  et al. [59]  In vitro studies of recombinant human adiponectin and reconstituted LPS show that adiponectin binds LPS and 
   suppresses  LAL
2007 Anderson  et al. [55]  No signifi  cant alteration in adiponectin levels in endotoxaemia, but downregulation of adiponectin receptor mRNA 
    in white cells (healthy subjects n = 20, 50% male)
2009 Jernås  et al. [63]  Lower levels of adiponectin during intensive care stay compared with recovery (subarachnoid haemorrhage n = 8)
2009   Venkatesh et al. [64]  Lower levels of adiponectin in critically ill cohort, with a strong association between plasma cortisol and adiponectin 
    and an inverse correlation between adiponectin and CRP (critically ill n = 20; historical controls n = 16)
2009 Langouche  et al. [65]  Lower levels of circulating adiponectin in ICU patients on admission; these levels increased to normal reference 
    values during the ICU stay. Intensive insulin therapy increased the rise of adiponectin over time in ICU. Critically ill 
    n = 318, healthy subjects n = 22, acutely stressed subjects n = 22
2010 Kaplan  et al. [69]  Increased levels of HMW adiponectin on day 1 in paediatric septic shock cohort (SIRS/sepsis n = 22, septic shock 
    n = 25, control n = 27)
2010 Hillenbrand  et al. [58]  Lower levels of adiponectin in septic patients with negative correlation with SOFA scores (septic shock n = 33, 
    control (blood donors) n = 60, morbidly obese n = 37)
2010 Walkey  et al. [68]  Higher levels of adiponectin at baseline associated with increased 28-day mortality (acute respiratory failure n = 175)
CRP, C-reactive protein; HMW, high-molecular weight; LAL, limulus amoebocyte lysate; LPS, lipopolysaccharidase; SIRS, systemic infl  ammatory response syndrome; 
SOFA, Sequential Organ Failure Assessment.
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In critical illness, is survival inﬂ   uenced by baseline 
adiponectin levels, and would the ability to increase 
adiponectin and/or the HMW component via either 
altered expression, altered secretion from the fat cell or 
altered clearance confer prognostic signiﬁ  cance? Th  ese 
questions will need to be examined in future studies.
Key messages
• Adiponectin is an adipokine with insulin-sensitising 
and vascular-protective properties.
•  Adiponectin also has anti-inﬂ  ammatory properties.
•  Preliminary data suggest low levels of adiponectin in 
critical illness.
• Th  e signiﬁ  cance of these observations needs further 
elucidation.
• Th  e various therapeutic options to raise circulating 
levels are discussed.
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